The patent (European patent EP 1664322) covers iBio's carrier molecule fusion protein technology (iBioModulator™) for therapeutic proteins and vaccines.
"This is an important extension of intellectual property protection for our commercial technology platform," said
An immunomodulator is a substance that alters the immune response. Animal studies have shown that the iBioModulator platform can increase the strength of the immune response specific to a vaccine antigen (as measured by antibody titer). Commercial applications of this proprietary platform include the development of more effective vaccines.
Among the positive tests completed to demonstrate the ability of the iBioModulator platform to improve the performance of vaccines are the following:
• An iBioModulator-Pfs 25 antigen malaria vaccine candidate in advanced pre-IND testing elicited transmission blocking activity at lower doses and for a longer period of time following immunization compared to a vaccine candidate containing the antigen alone; titers of specific immunoglobulins to Pfs 25 were approximately ten-fold higher across dose levels when the iBioModulator was used.
• Therapeutic human papillomavirus (HPV) vaccine candidates constructed with iBioModulator provided superior protection from HPV-16 E7-induced tumors and extended survival in a mouse model when compared with vaccination with native E7 protein alone. The HPV tumor protection was both prophylactic and therapeutic. It produced tumor-free survival of mice immunized with the E7 iBioModulator antigen. Effective therapeutic vaccination to treat HPV-induced cancer has been a long-desired but difficult to achieve objective of healthcare professionals. The iBioModulator platform offers a new and promising approach to addressing this important goal.
• iBioModulator has been used as a fusion to express peptide or protein domain antigens in a number of other successful vaccine candidates, including those for anthrax, plague, sleeping sickness and influenza.
• The iBioModulator also has been used by scientists at the
The patent, entitled "RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES," is based on an invention developed by scientists at the company's research and technology collaborator, the
Most Popular Stories
- 'Lucy's' Super Powers Tops 'Hercules' at Box Office
- The Rise and Fall of Richard Alarcon
- The 2014 Fastest-Growing 100
- Vancrest Assisted Living Project to Add 20 Jobs
- Fighting Blocks Investigators, Police From MH17 Crash Site
- U.N. Renews Demand for Gaza Cease-Fire
- Nissan Profits Rise on Growth in U.S., China
- 'Sharknado' Sequel Has Bite and Lots of Laughs
- VW Site Could Mean Another 2,000 Jobs for Chattanooga
- Pending Home Sales Slipped in June